| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.
|
Biol Blood Marrow Transplant
|
2005
|
19.83
|
|
2
|
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
|
Cancer Cell
|
2005
|
17.41
|
|
3
|
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
|
PLoS Med
|
2006
|
7.95
|
|
4
|
Peripheral-blood stem cells versus bone marrow from unrelated donors.
|
N Engl J Med
|
2012
|
6.30
|
|
5
|
Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.
|
J Clin Oncol
|
2002
|
4.69
|
|
6
|
Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report.
|
Biol Blood Marrow Transplant
|
2006
|
4.09
|
|
7
|
Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria.
|
Blood
|
2011
|
4.03
|
|
8
|
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.
|
Blood
|
2004
|
3.61
|
|
9
|
Rituximab for steroid-refractory chronic graft-versus-host disease.
|
Blood
|
2006
|
3.08
|
|
10
|
Risk factors for acute GVHD and survival after hematopoietic cell transplantation.
|
Blood
|
2011
|
3.02
|
|
11
|
Sentinel lymph node biopsy for evaluation and treatment of patients with Merkel cell carcinoma: The Dana-Farber experience and meta-analysis of the literature.
|
Arch Dermatol
|
2006
|
2.92
|
|
12
|
Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission.
|
Blood
|
2004
|
2.89
|
|
13
|
Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis.
|
Blood
|
2011
|
2.66
|
|
14
|
Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease.
|
Blood
|
2005
|
2.65
|
|
15
|
Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report.
|
Biol Blood Marrow Transplant
|
2006
|
2.63
|
|
16
|
Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report.
|
Biol Blood Marrow Transplant
|
2006
|
2.44
|
|
17
|
Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD.
|
Blood
|
2009
|
2.44
|
|
18
|
Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation.
|
Blood
|
2003
|
2.36
|
|
19
|
Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium.
|
Blood
|
2011
|
2.36
|
|
20
|
Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age.
|
Blood
|
2004
|
2.30
|
|
21
|
Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria.
|
Blood
|
2011
|
2.26
|
|
22
|
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report.
|
Biol Blood Marrow Transplant
|
2006
|
2.24
|
|
23
|
Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium.
|
Blood
|
2012
|
2.19
|
|
24
|
Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy.
|
Blood
|
2013
|
2.12
|
|
25
|
Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2011
|
2.11
|
|
26
|
HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2010
|
2.04
|
|
27
|
A disease risk index for patients undergoing allogeneic stem cell transplantation.
|
Blood
|
2012
|
2.00
|
|
28
|
Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study.
|
Blood
|
2005
|
1.95
|
|
29
|
Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease.
|
Blood
|
2013
|
1.94
|
|
30
|
Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2004
|
1.91
|
|
31
|
Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation.
|
Blood
|
2011
|
1.90
|
|
32
|
Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis.
|
J Clin Oncol
|
2013
|
1.88
|
|
33
|
Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation.
|
Biol Blood Marrow Transplant
|
2006
|
1.87
|
|
34
|
Evaluation of HLA matching in unrelated hematopoietic stem cell transplantation for nonmalignant disorders.
|
Blood
|
2012
|
1.86
|
|
35
|
Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report.
|
Biol Blood Marrow Transplant
|
2006
|
1.86
|
|
36
|
Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality.
|
Blood
|
2013
|
1.84
|
|
37
|
Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation.
|
J Clin Oncol
|
2010
|
1.84
|
|
38
|
JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.
|
Br J Haematol
|
2005
|
1.81
|
|
39
|
Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation.
|
Blood
|
2003
|
1.73
|
|
40
|
Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2005
|
1.70
|
|
41
|
One-antigen mismatched related versus HLA-matched unrelated donor hematopoietic stem cell transplantation in adults with acute leukemia: Center for International Blood and Marrow Transplant Research results in the era of molecular HLA typing.
|
Biol Blood Marrow Transplant
|
2010
|
1.69
|
|
42
|
Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors.
|
J Clin Oncol
|
2013
|
1.66
|
|
43
|
The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera.
|
Cancer
|
2006
|
1.64
|
|
44
|
Association of depressive syndrome and early deaths among patients after stem-cell transplantation for malignant diseases.
|
J Clin Oncol
|
2002
|
1.55
|
|
45
|
A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change.
|
Biol Blood Marrow Transplant
|
2011
|
1.54
|
|
46
|
Race and socioeconomic status influence outcomes of unrelated donor hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2009
|
1.52
|
|
47
|
Validation of measurement scales in ocular graft-versus-host disease.
|
Ophthalmology
|
2011
|
1.50
|
|
48
|
Economics of hematopoietic cell transplantation.
|
Blood
|
2012
|
1.47
|
|
49
|
Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens.
|
Biol Blood Marrow Transplant
|
2005
|
1.44
|
|
50
|
End points to establish the efficacy of new agents in the treatment of acute leukemia.
|
Blood
|
2006
|
1.43
|
|
51
|
Access to hematopoietic stem cell transplantation: effect of race and sex.
|
Cancer
|
2010
|
1.43
|
|
52
|
Costs of allogeneic hematopoietic cell transplantation with high-dose regimens.
|
Biol Blood Marrow Transplant
|
2008
|
1.41
|
|
53
|
Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease.
|
Nat Genet
|
2009
|
1.40
|
|
54
|
Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation.
|
Blood
|
2002
|
1.38
|
|
55
|
Validation of the human activity profile questionnaire in patients after allogeneic hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2010
|
1.38
|
|
56
|
Trends in survival rates after allogeneic hematopoietic stem-cell transplantation for acute and chronic leukemia by ethnicity in the United States and Canada.
|
J Clin Oncol
|
2003
|
1.38
|
|
57
|
Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.
|
Biol Blood Marrow Transplant
|
2006
|
1.34
|
|
58
|
Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors.
|
Blood
|
2010
|
1.33
|
|
59
|
Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study.
|
Haematologica
|
2011
|
1.32
|
|
60
|
Malignant hematologic diseases in adolescents and young adults.
|
Blood
|
2011
|
1.32
|
|
61
|
Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age.
|
Biol Blood Marrow Transplant
|
2013
|
1.31
|
|
62
|
Multiple mismatches at the low expression HLA loci DP, DQ, and DRB3/4/5 associate with adverse outcomes in hematopoietic stem cell transplantation.
|
Blood
|
2013
|
1.31
|
|
63
|
Prevalence of hematopoietic cell transplant survivors in the United States.
|
Biol Blood Marrow Transplant
|
2013
|
1.30
|
|
64
|
Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study.
|
Blood
|
2003
|
1.29
|
|
65
|
Private cord blood banking: experiences and views of pediatric hematopoietic cell transplantation physicians.
|
Pediatrics
|
2009
|
1.29
|
|
66
|
Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
|
Blood
|
2004
|
1.27
|
|
67
|
Meeting the challenge of hematologic malignancies in sub-Saharan Africa.
|
Blood
|
2012
|
1.26
|
|
68
|
How I treat late effects in adults after allogeneic stem cell transplantation.
|
Blood
|
2010
|
1.26
|
|
69
|
Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease.
|
Blood
|
2009
|
1.25
|
|
70
|
Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2010
|
1.25
|
|
71
|
Direct-to-consumer advertising in oncology: a content analysis of print media.
|
J Clin Oncol
|
2007
|
1.25
|
|
72
|
Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease.
|
Brain
|
2010
|
1.24
|
|
73
|
Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation.
|
Ann Intern Med
|
2011
|
1.23
|
|
74
|
Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse.
|
Biol Blood Marrow Transplant
|
2009
|
1.23
|
|
75
|
Relationship of race/ethnicity and survival after single umbilical cord blood transplantation for adults and children with leukemia and myelodysplastic syndromes.
|
Biol Blood Marrow Transplant
|
2011
|
1.21
|
|
76
|
Identification of a permissible HLA mismatch in hematopoietic stem cell transplantation.
|
Blood
|
2014
|
1.20
|
|
77
|
Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia.
|
Br J Haematol
|
2007
|
1.20
|
|
78
|
Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease.
|
Blood
|
2013
|
1.18
|
|
79
|
Transplantation's greatest challenges: advances in chronic graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2007
|
1.18
|
|
80
|
The preventive health behaviors of long-term survivors of cancer and hematopoietic stem cell transplantation compared with matched controls.
|
Biol Blood Marrow Transplant
|
2009
|
1.18
|
|
81
|
Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation.
|
J Clin Oncol
|
2011
|
1.17
|
|
82
|
Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States.
|
Blood
|
2004
|
1.16
|
|
83
|
Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma.
|
Biol Blood Marrow Transplant
|
2009
|
1.14
|
|
84
|
Sensitivity of changes in chronic graft-versus-host disease activity to changes in patient-reported quality of life: results from the Chronic Graft-versus-Host Disease Consortium.
|
Haematologica
|
2011
|
1.13
|
|
85
|
Treatment of chronic graft-versus-host disease: Past, present and future.
|
Korean J Hematol
|
2011
|
1.11
|
|
86
|
Clinical benefit of response in chronic graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2012
|
1.10
|
|
87
|
Diagnosis and treatment of ocular chronic graft-versus-host disease: report from the German-Austrian-Swiss Consensus Conference on Clinical Practice in chronic GVHD.
|
Cornea
|
2012
|
1.10
|
|
88
|
Plasma CXCL9 elevations correlate with chronic GVHD diagnosis.
|
Blood
|
2013
|
1.08
|
|
89
|
Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease.
|
Blood
|
2011
|
1.05
|
|
90
|
Assessment of joint and fascia manifestations in chronic graft-versus-host disease.
|
Arthritis Rheumatol
|
2014
|
1.04
|
|
91
|
Outcomes after hematopoietic stem-cell transplantation for hematologic malignancies in patients with or without advance care planning.
|
J Clin Oncol
|
2007
|
1.02
|
|
92
|
Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.
|
Blood
|
2002
|
1.02
|
|
93
|
Analysis of gastrointestinal and hepatic chronic graft-versus-host [corrected] disease manifestations on major outcomes: a chronic graft-versus-host [corrected] disease consortium study.
|
Biol Blood Marrow Transplant
|
2013
|
1.01
|
|
94
|
Delivering care to long-term adult survivors of hematopoietic cell transplantation.
|
J Clin Oncol
|
2012
|
1.01
|
|
95
|
Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study.
|
Blood
|
2003
|
1.01
|
|
96
|
Poor agreement between clinician response ratings and calculated response measures in patients with chronic graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2012
|
1.00
|
|
97
|
Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation.
|
J Clin Oncol
|
2013
|
0.99
|
|
98
|
HLA-allele matched unrelated donors compared to HLA-matched sibling donors: role of cell source and disease risk category.
|
Biol Blood Marrow Transplant
|
2010
|
0.97
|
|
99
|
Outcomes of allogeneic hematopoietic cell transplantation for adolescent and young adults compared with children and older adults with acute myeloid leukemia.
|
Biol Blood Marrow Transplant
|
2011
|
0.95
|
|
100
|
Increased BCR responsiveness in B cells from patients with chronic GVHD.
|
Blood
|
2014
|
0.93
|
|
101
|
Patients' reflections on communication in the second-opinion hematology-oncology consultation.
|
Patient Educ Couns
|
2009
|
0.91
|
|
102
|
Factors associated with adherence to preventive care practices among hematopoietic cell transplantation survivors.
|
Biol Blood Marrow Transplant
|
2010
|
0.90
|
|
103
|
The impact of HLA unidirectional mismatches on the outcome of myeloablative hematopoietic stem cell transplantation with unrelated donors.
|
Blood
|
2013
|
0.90
|
|
104
|
Chronic Graft-versus-Host Disease--implementation of the National Institutes of Health Consensus Criteria for Clinical Trials.
|
Biol Blood Marrow Transplant
|
2008
|
0.89
|
|
105
|
Insufficient evidence for association of NOD2/CARD15 or other inflammatory bowel disease-associated markers on GVHD incidence or other adverse outcomes in T-replete, unrelated donor transplantation.
|
Blood
|
2010
|
0.89
|
|
106
|
Advance care planning in patients undergoing hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2007
|
0.89
|
|
107
|
Hand grip strength and 2-minute walk test in chronic graft-versus-host disease assessment: analysis from the Chronic GVHD Consortium.
|
Biol Blood Marrow Transplant
|
2013
|
0.88
|
|
108
|
Differences in characteristics of US hematopoietic stem cell transplantation centers by proportion of racial or ethnic minorities.
|
Biol Blood Marrow Transplant
|
2005
|
0.88
|
|
109
|
Variation in management of immune suppression after allogeneic hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2011
|
0.87
|
|
110
|
Clinical evaluation of oral chronic graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2008
|
0.87
|
|
111
|
Outpatient management following intensive induction chemotherapy for myelodysplastic syndromes and acute myeloid leukemia: a pilot study.
|
Haematologica
|
2011
|
0.87
|
|
112
|
Activation and expansion of CD8(+) T effector cells in patients with chronic graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2011
|
0.86
|
|
113
|
Outcomes of hematologic malignancies after unrelated donor hematopoietic cell transplantation according to place of residence.
|
Biol Blood Marrow Transplant
|
2009
|
0.86
|
|
114
|
Glucocorticoids and insulin resistance in children with acute lymphoblastic leukemia.
|
Pediatr Blood Cancer
|
2012
|
0.85
|
|
115
|
Effects of obstetric factors and storage temperatures on the yield of endothelial colony forming cells from umbilical cord blood.
|
Angiogenesis
|
2011
|
0.84
|
|
116
|
Graft-versus-host disease: state of the science.
|
Biol Blood Marrow Transplant
|
2012
|
0.84
|
|
117
|
Coping styles, health status and advance care planning in patients with hematologic malignancies.
|
Leuk Lymphoma
|
2011
|
0.83
|
|
118
|
Acute graft versus host disease after orthotopic liver transplantation.
|
J Hematol Oncol
|
2012
|
0.83
|
|
119
|
Methodological and logistical considerations to study design and data collection in racial/ethnic minority populations evaluating outcome disparity in hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2009
|
0.83
|
|
120
|
Information giving and receiving in hematological malignancy consultations.
|
Psychooncology
|
2011
|
0.81
|
|
121
|
Costs of second allogeneic hematopoietic cell transplantation.
|
Transplantation
|
2013
|
0.80
|
|
122
|
Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life.
|
Blood
|
2014
|
0.80
|
|
123
|
The outcomes of family haploidentical hematopoietic stem cell transplantation in hematologic malignancies are not associated with patient age.
|
Biol Blood Marrow Transplant
|
2010
|
0.80
|
|
124
|
Physician communication styles in initial consultations for hematological cancer.
|
Patient Educ Couns
|
2013
|
0.79
|
|
125
|
[Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation].
|
Rinsho Ketsueki
|
2014
|
0.78
|
|
126
|
Analysis of non-HLA genomic risk factors in HLA-matched unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia.
|
Haematologica
|
2012
|
0.78
|
|
127
|
Preservation of fertility in patients with cancer.
|
N Engl J Med
|
2009
|
0.77
|
|
128
|
Late critical problems in transplantation: an historical perspective.
|
Hematology Am Soc Hematol Educ Program
|
2008
|
0.77
|
|
129
|
Limiting the daily total nucleated cell dose of cryopreserved peripheral blood stem cell products for autologous transplantation improves infusion-related safety with no adverse impact on hematopoietic engraftment.
|
Biol Blood Marrow Transplant
|
2011
|
0.77
|
|
130
|
Role of skin biopsy to confirm suspected acute graft-vs-host disease: results of decision analysis.
|
Arch Dermatol
|
2006
|
0.77
|
|
131
|
Birth order and transplantation outcome in HLA-identical sibling stem cell transplantation: an analysis on behalf of the Center for International Blood and Marrow Transplantation.
|
Biol Blood Marrow Transplant
|
2013
|
0.75
|
|
132
|
Re: An approach to predicting HSCT outcome using HLA-mismatch information mapped on protein structure data.
|
Biol Blood Marrow Transplant
|
2010
|
0.75
|
|
133
|
Erratum to "Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study" [Biol Blood Marrow Transplant 2016;22:1410-1415].
|
Biol Blood Marrow Transplant
|
2016
|
0.75
|